Quarterly report [Sections 13 or 15(d)]

SEGMENT INFORMATION (Tables)

v3.26.3
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
SCHEDULE OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

    2026     2025     2026     2025  
    For The Three Months Ended     For The Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
                         
Revenue, net:   $ 10,373     $ 8,756     $ 28,537     $ 29,504  
Less:                                
Cost of revenue:                                
Fixed     1,754       1,736       5,220       5,120  
Variable     1,439       1,581       4,579       6,298  
Operating and other expenses:                                
Sales and marketing     2,704       2,087       7,088       7,811  
Research and development     160       150       461       500  
General and administrative     6,716       2,057       12,143       7,268  
Interest & other expense, net     (15 )     145       (33 )     268  
(Benefit) provision for income taxes     (884 )     (11 )     (517 )     7  
Segment net (loss) income     (1,501 )     1,011       (404 )     2,232  
Reconciliation of profit or loss:                                
Loss on discontinued operations     (109 )     (100 )     (327 )     (314 )
Consolidated net (loss) income   $ (1,610 )   $ 911     $ (731 )   $ 1,918  
SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA

    2026     2025     2026     2025  
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
(Loss) income from continuing operations (GAAP Basis)   $ (1,501 )   $ 1,011     $ (404 )   $ 2,232  
Depreciation and amortization     141       111       386       307  
Stock-based compensation     3,993       7       4,001       31  
Non-recurring legal expenses     234       -       614       -  
Severance & related expense     -       -       -       692  
Asset impairment - lab supplies     -       -       -       198  
Loss on sale of asset     104       -       104       -  
Lab supplies write-off     -       -       217       -  
Taxes (benefit) expense     (884 )     (11 )     (517 )     7  
Note payable interest     -       30       -       156  
Other income/expense, net     (15 )     10       (33 )     25  
Change in fair value of note payable     -       105       -       87  
Adjusted EBITDA   $ 2,072     $ 1,263     $ 4,368     $ 3,735